In many low- and middle-income countries, it can be difficult for people living with non-communicable diseases (NCDs) to access the care they need. Those living with NCDs – like cancer, diabetes, cardiovascular diseases, chronic respiratory diseases, and mental health conditions – often struggle to take care of themselves and their loved ones. And the situation becomes even more burdensome with age.
Every day, thousands of individuals work in different capacities toward the global elimination of trachoma, a neglected tropical disease (NTD) and the world’s leading infectious cause of blindness. From manufacturing the antibiotic used to help treat trachoma, to distributing medication in affected communities, to performing surgery on those suffering from trichiasis, the blinding stage of trachoma, the roles in the fight to eliminate this disease are wide-ranging.
An individual’s ability to access quality health care is often limited where infrastructure is weak or non-existent. By supporting collaborative and entrepreneurial approaches that aim to build and improve health infrastructure, we are giving organizations and individuals the skills and resources they need to drive better global health outcomes.
In today’s ever-changing healthcare environment, new and creative solutions are needed to accelerate advances in global health and development. Pfizer is responding to this new global picture by focusing on locally driven and collaborative approaches that aim to break down healthcare access barriers, address the health needs of individuals and support long-term capacity building.
Through a Highly Orchestrated Supply Network (HOSuN) approach, Pfizer has developed a supply chain that is directly sensitive to patient needs and can speed our response to those needs. Enhanced with technological advances, we are able to track movement of product throughout the entire supply chain.
Pfizer has had two successful Greenhouse Gas (GHG) reduction goals which resulted in reductions of GHG emissions by roughly half from 2000 to 2014. We are working hard to meet our third GHG reduction goal to reduce emissions 20 percent further by 2020 from a 2012 baseline. This latest goal has been recognized as a Science Based Target by an initiative led by the Carbon Disclosure Project, the United Nations Global Compact, the World Resources Institute and the World Wildlife Fund.
Compared with a 2012 baseline, by the end of 2020 Pfizer has the goal to reduce: